PPD partnered with Takeda to develop the compound. Under PPD’s agreement with Takeda, the FDA’s acceptance of the NDA filing triggers a $15 million milestone payment to PPD.
Fred Eshelman, PPD’s CEO, said: “We are pleased to partner with Takeda, one of the leading pharmaceutical companies in the area of diabetes. We are also delighted that this important regulatory milestone has been achieved as a result of close cooperation between Takeda and our company.”